The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."
The firm said that prior to obtaining US regulatory clearance, it's making the assay available for use as a lab-developed test by US laboratories with CLIA approvals.
Molecular Autopsy Consortium of Houston members outlined their recommendations for using molecular autopsy to investigate unexplained deaths in young people.
Six percent of patients diagnosed by exome sequencing received more than one molecular diagnosis, which can be important for their clinical management.
NEW YORK (GenomeWeb) – Foundation Medicine today said that it has signed a licensing deal with WuXi PharmaTech, enabling that firm to offer Foundation Medicine's genomic profiling technology to companies conducting clinical trials in China.
NEW YORK (GenomeWeb) – Despite a recent study that suggested array-based non-invasive prenatal testing may be an effective alternative to next-generation sequencing-based tests, Illumina appears unconcerned that its customers will switch platforms.
